2025 PACUPrep BCCCP Preparatory Course Acid–Base Disorders Supportive Care, Ventilation, and Complication Management
Supportive Care in Acid-Base Disorders

Supportive Care, Ventilation, and Complication Management

Objective Icon A clipboard with a checkmark, symbolizing clinical objectives.

Objective

Recommend supportive care and monitoring strategies to manage complications arising from acid–base disorders and their treatments.

1. Mechanical Ventilation Adjustments in Respiratory Disorders

Precise ventilator management is critical in primary respiratory acid–base disturbances. The primary goals are to ensure adequate oxygenation and ventilation while minimizing ventilator-induced lung injury (VILI). Gradual correction of PaCO₂, adherence to low tidal volumes, and careful titration of PEEP and FiO₂ are essential to prevent complications like barotrauma and cerebral ischemia.

Clinical Pearl Icon A lightbulb icon, symbolizing a clinical pearl or key insight. Key Pearls in Ventilator Management
  • Avoid Rapid Correction: In patients with chronic hypercapnia, avoid rapid drops in PaCO₂ (>10 mm Hg in 24 hours). A slower correction rate (≤2–5 mm Hg per day) prevents post-hypercapnic metabolic alkalosis and neurologic sequelae.
  • Lung Protective Strategy: Adhere to low tidal volume (VT) ventilation (6 mL/kg predicted body weight) and maintain a plateau pressure ≤30 cm H₂O to minimize barotrauma.
  • Permissive Hypercapnia: In ARDS, tolerating a moderate level of hypercapnia (allowing pH to fall to ≥7.20) is an acceptable strategy to reduce VILI, provided there are no contraindications like severe intracranial hypertension.

A. Indications and Targets for Ventilator Adjustment

  • Indications for Setting Changes:
    • Respiratory Acidosis: pH < 7.30 with PaCO₂ > 50 mm Hg despite current settings.
    • Respiratory Alkalosis: pH > 7.55 with PaCO₂ < 30 mm Hg causing clinical concern.
  • Therapeutic Targets:
    • Arterial pH: 7.30–7.45.
    • PaCO₂: Near the patient’s known chronic baseline, when applicable.
    • Oxygenation: SpO₂ 88–95% or PaO₂ 55–80 mm Hg to avoid both hypoxia and hyperoxia.

B. Parameter Titration Strategy

Ventilator adjustments should follow established lung-protective principles, such as those from the ARDSNet protocol.

Ventilator Parameter Titration Guide
Parameter Target/Method Rationale
Tidal Volume (VT) 6 mL/kg predicted body weight (PBW) Minimizes alveolar overdistension and volutrauma.
Respiratory Rate (RR) Increase to improve minute ventilation (up to 25-30 breaths/min) Primary method to control PaCO₂ in a low-VT strategy. Monitor for auto-PEEP.
PEEP/FiO₂ Use a PEEP/FiO₂ ladder to maintain SpO₂ target Optimizes alveolar recruitment while minimizing FiO₂ toxicity.
Advanced Strategy Extracorporeal CO₂ Removal (ECCO₂R) Allows for ultra-protective ventilation (VT ≈4 mL/kg) in severe ARDS.

Case Vignette

A 68-year-old man with COPD and chronic hypercapnia (baseline PaCO₂ 60 mm Hg) develops acute respiratory acidosis (pH 7.20, PaCO₂ 75 mm Hg). The team correctly increases the respiratory rate by 4 breaths/min and reduces the tidal volume from 8 to 6 mL/kg PBW. They plan to monitor neurologic status and repeat the ABG in 4 hours, aiming for a gradual PaCO₂ reduction.

2. Prevention of ICU-Related Complications

Management of acid-base disorders occurs within the complex ICU environment. Proactive integration of care bundles for infection control, gastrointestinal (GI) prophylaxis, and electrolyte management is essential to reduce overall morbidity and mortality.

Clinical Pearl Icon A lightbulb icon, symbolizing a clinical pearl or key insight. Key Pearls in Complication Prevention
  • Assess Line Necessity Daily: The single most effective measure to reduce central line-associated bloodstream infections (CLABSI) is to remove nonessential catheters promptly.
  • Balance GI Prophylaxis Risks: While necessary for high-risk patients, acid-suppressive therapy (especially PPIs) is associated with increased risk of C. difficile and nosocomial pneumonia. Reassess the need daily.
  • Correct Magnesium First: In cases of refractory hypokalemia, coexisting hypomagnesemia is often the culprit. Correcting magnesium levels is necessary for effective potassium repletion.

A. Vascular Catheter Infection Control

  • Use maximal sterile barrier precautions during insertion (cap, mask, sterile gown/gloves, full-body drape).
  • Prepare skin with chlorhexidine antisepsis before insertion.
  • Consider using antiseptic-impregnated catheters and dressings in high-risk populations.
  • Perform daily reviews of all catheter necessities and remove them as soon as they are no longer indicated.

B. Stress Ulcer Prophylaxis (SUP)

Stress Ulcer Prophylaxis Guidelines
Indication Agent & Dose Key Monitoring
Mechanical ventilation >48h OR Coagulopathy (Platelets <50, INR >1.5) Pantoprazole 40 mg IV daily OR Famotidine 20 mg IV q12h Monitor for signs of nosocomial pneumonia and C. difficile. Reassess need for SUP daily.

C. Electrolyte Repletion

  • Potassium: Target 4.0–4.5 mEq/L. For K⁺ < 3.5 mEq/L, administer KCl 20–40 mEq IV over 2–4 hours. Use continuous ECG monitoring for infusions if K⁺ < 3.0 mEq/L.
  • Magnesium: Target >2.0 mg/dL. For Mg²⁺ < 1.5 mg/dL, administer MgSO₄ 2 g IV over 2 hours.

3. Management of Iatrogenic Complications

Therapeutic interventions for acid-base disorders, particularly sodium bicarbonate administration, can lead to significant iatrogenic complications. Clinicians must anticipate and mitigate fluid overload and electrolyte disturbances that arise from these treatments.

Clinical Pearl Icon A lightbulb icon, symbolizing a clinical pearl or key insight. Key Pearls in Managing Treatment Complications
  • Infuse Bicarbonate Slowly: Avoid rapid IV boluses of sodium bicarbonate, which can cause hypernatremia, volume overload, and paradoxical intracellular acidosis. Infuse calculated doses over 4–6 hours and reassess with a repeat ABG.
  • Anticipate Volume Overload: Each ampule of bicarbonate delivers a significant sodium load. Be prepared to manage resultant fluid overload with diuretics or, if refractory, renal replacement therapy.
  • Hypokalemia Worsens Alkalosis: Metabolic alkalosis promotes renal potassium wasting, and the resulting hypokalemia perpetuates the alkalosis. Prompt and aggressive potassium repletion is crucial to break this cycle.

A. Fluid Overload from Sodium Bicarbonate

Sodium bicarbonate is indicated for severe metabolic acidosis (pH ≤ 7.15) with associated hemodynamic compromise or acute kidney injury. The large sodium load requires careful monitoring.

Management of Bicarbonate-Induced Fluid Overload A flowchart showing the decision pathway for managing fluid overload after sodium bicarbonate administration. It starts with assessing fluid status, moves to diuretic therapy, and ends with considering CRRT for refractory cases. Sodium Bicarbonate Infusion Initiated Assess for Fluid Overload(↑CVP, Rales, Edema) Administer IV Furosemide Continue Monitoring No Overload Overload Present If Refractory, Initiate CRRT
Figure 1: Management Algorithm for Bicarbonate-Induced Fluid Overload. Careful monitoring for signs of volume overload is essential after bicarbonate administration. Diuretics are the first-line therapy, with CRRT reserved for refractory or anuric patients.

B. Hypokalemia Secondary to Metabolic Alkalosis

  • Mechanism: Alkalosis drives potassium into cells and enhances renal potassium secretion in exchange for hydrogen ions, leading to and perpetuating hypokalemia.
  • Replacement: Administer KCl 20 mEq IV over 2 hours for K⁺ 3.0–3.4 mEq/L, and up to 40 mEq for K⁺ < 3.0 mEq/L. Always correct co-existing hypomagnesemia first.

C. Pharmacologic Correction of Severe Metabolic Alkalosis

  • Acetazolamide: 500 mg IV once daily can be used to promote renal bicarbonate excretion, typically lowering serum HCO₃⁻ by 2–5 mEq/L in 24 hours.
  • Hydrochloric Acid Infusion: Reserved for life-threatening metabolic alkalosis (pH > 7.55) refractory to other measures. Requires central line administration and close monitoring.

4. Multidisciplinary Goals of Care Conversations

Decisions regarding the initiation or continuation of life-sustaining therapies like renal replacement therapy (RRT) and prolonged mechanical ventilation must be grounded in shared decision-making. These conversations should align medical possibilities with the patient’s values and goals.

Clinical Pearl Icon A lightbulb icon, symbolizing a clinical pearl or key insight. Key Pearls in Shared Decision-Making
  • Use a Structured Framework: Employ communication frameworks (e.g., SPIKES) for family meetings to ensure all critical elements are covered, including setting, perception, invitation, knowledge, emotions, and summary.
  • Involve Palliative Care Early: Early consultation with palliative care specialists can help clarify goals of care, manage symptoms, and support families, potentially avoiding non-beneficial interventions.

A. Renal Replacement Therapy (RRT) Initiation

  • KDIGO Indications: Consider RRT for life-threatening complications such as refractory hyperkalemia, severe metabolic acidosis (pH < 7.15), diuretic-unresponsive volume overload, or uremic complications (e.g., pericarditis, encephalopathy).
  • Holistic Consideration: The decision to start RRT must incorporate the patient’s overall prognosis, personal values, and goals of care.
  • Pharmacist Role: The clinical pharmacist is crucial for adjusting drug dosing for RRT clearance and monitoring anticoagulation effects on the patient’s acid-base status.

B. Weaning vs. Prolonged Mechanical Ventilation

  • Extubation Readiness Criteria: Assess daily for readiness, including resolved or stable underlying cause, pH > 7.30, FiO₂ ≤ 0.40, PEEP ≤ 8 cm H₂O, and hemodynamic stability.
  • Weaning Protocols: Implement protocols that include daily sedation interruptions and spontaneous breathing trials (SBTs) to identify the earliest opportunity for liberation from the ventilator.

C. The Multidisciplinary Care Conference

Convene regular family conferences involving the core ICU team (physician, nurse), clinical pharmacist, respiratory therapist, and palliative care. Discuss realistic outcomes, including the burdens and benefits of continuing organ support, to ensure care remains aligned with the patient’s wishes.

References

  1. Fan E, Brodie D, Slutsky AS. Mechanical ventilation in adult ARDS. Am J Respir Crit Care Med. 2017;195(9):1253–63.
  2. Papazian L, et al. Management of ARDS: formal guidelines. Ann Intensive Care. 2019;9:69.
  3. Hickling KG, et al. Permissive hypercapnia. Crit Care. 2004;8(4):284–89.
  4. Slutsky AS. Preventing complications of mechanical ventilation. Am J Respir Crit Care Med. 1996;153(1):S3–S9.
  5. Jacobs R, Sablon A, Spapen H. ECCO₂R during CRRT. Respir Care. 2020;65(4):517–24.
  6. O’Grady NP, et al. Guidelines for prevention of catheter-related infections. Clin Infect Dis. 2011;52:e162–93.
  7. Cook DJ, et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med. 1994;330(6):377–81.
  8. Emmett M. Metabolic alkalosis: brief pathophysiologic review. Clin J Am Soc Nephrol. 2020;15(12):1848–56.
  9. Jaber S, et al. Sodium bicarbonate therapy in severe metabolic acidaemia (BICAR-ICU). Lancet. 2018;392(10141):31–40.
  10. Dickerson RN. Fluids, electrolytes, acid–base disorders, and nutrition support. In: ACCP/SCCM Critical Care Pharmacy Preparatory Review. 2016.
  11. Dickerson RN. Fluid overload in critically ill patients: pathophysiology and management. Crit Care Clin. 2009;25(4):705–17.
  12. Gennari FJ. Hypokalemia. N Engl J Med. 1998;339(7):451–58.
  13. Marik PE, et al. Acetazolamide in metabolic alkalosis. Heart Lung. 1991;20(5):455–59.
  14. Guffey JD, et al. Hydrochloric acid infusion for metabolic alkalosis. Ann Pharmacother. 2018;52(5):522–26.
  15. Curtis JR, White DB. Practical guidance for ICU family conferences. Chest. 2008;134(4):835–43.
  16. Khwaja A. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2(1):1–138.
Previous Topic
Back to Lesson
Next Topic